For research use only. Not for therapeutic Use.
MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC50 of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC50s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE[1][2][3].
MBCQ (compound 3d) induces relaxation of isolated porcine coronary arteries precontracted with prostaglandin F2α (PGF2α; EC50=190 nM)[1].
MBCQ (0.01-10 μM; 10 min) inhibits Carbachol (10 μM)-induced contractions in a concentration-dependent manner in rat ileal smooth muscle[3].
| Catalog Number | M133296 |
| CAS Number | 150450-53-6 |
| Synonyms | N-(1,3-benzodioxol-5-ylmethyl)-6-chloroquinazolin-4-amine |
| Molecular Formula | C16H12ClN3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H12ClN3O2/c17-11-2-3-13-12(6-11)16(20-8-19-13)18-7-10-1-4-14-15(5-10)22-9-21-14/h1-6,8H,7,9H2,(H,18,19,20) |
| InChIKey | CNODHOSDWZLJGA-UHFFFAOYSA-N |
| SMILES | C1OC2=C(O1)C=C(C=C2)CNC3=NC=NC4=C3C=C(C=C4)Cl |
| Reference | [1]. Y Takase, et al. Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J Med Chem. 1994 Jun 24;37(13):2106-11. [2]. Jeffery D MacPherson, et al. Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation J Pharmacol Exp Ther. 2006 Apr;317(1):188-95. [3]. Takeharu Kaneda, et al. Lack of cyclic nucleotide regulation of MBCQ-induced relaxation of rat ileal smooth muscle. J Smooth Muscle Res. 2003 Jun;39(3):47-54. |
